Aquestive Therapeutics, Inc.
NASDAQ:AQSTDrug Manufacturers - Specialty & Generic
+$0.23 today
- Market cap
- $475.10M
- Beta
- 1.45
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.56
Volume 1.80M
Average 1.51M
AQST Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Aquestive Therapeutics, Inc.NASDAQ: AQST
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $10.9M, compared with -$3.13M a year earlier. Trailing-twelve-month accounts receivables was $3.65M.
Context
- Accounts receivables amounted to 23.3% of revenue in FY2025, up 21.4 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $10.9M or moves back toward the trailing-twelve-month quarterly average of $913.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (10.37M) USD
- Year-over-year change
- -1048.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.37M) | -1048.1% |
| FY2024 | 2024-12-31 | 1.09M | +135.6% |
| FY2023 | 2023-12-31 | (3.07M) | -141.8% |
| FY2022 | 2022-12-31 | 7.35M | +237.3% |
| FY2021 | 2021-12-31 | (5.35M) | — |
Accounts Receivables vs competitors
How AQST compares with its peers on the latest reported figures
- AQST's LTM Mar 2026 accounts receivables of $3.65M is the 7th largest of the 10 companies compared; the peer median is $6.59M.
- Its year-over-year change of +482.9% is the 2nd highest of 10, against a peer median of -39.9%.
- Accounts receivables amounts to 7.3% of revenue for AQST, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $59.21M | +1175.7% | +30.0% | 3.4% | |
| LTM Jun 2026 | $47.41M | -506.5% | +10.9% | 5.7% | |
| LTM Mar 2026 | $12.33M | +56.3% | +89.9% | 5.7% | |
| LTM Mar 2026 | $9.97M | +11.8% | -7.4% | 3.2% | |
| LTM Mar 2026 | $6.59M | -26.2% | +53.2% | 10.2% | |
| LTM Mar 2026 | $3.77M | -1221.0% | -5.0% | 9.0% | |
| LTM Mar 2026 | $3.65M | +482.9% | — | 7.3% | |
| LTM Mar 2026 | $2.98M | -39.9% | +20.9% | 2.4% | |
| LTM Mar 2026 | $2.84M | -56.6% | -14.3% | 0.4% | |
| LTM Mar 2026 | $60K | -99.4% | — | 0.0% | |
| Peer median (excluding AQST) | $6.59M | -39.9% | +15.9% | 3.4% | |
Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (70.54M) | (54.41M) | (7.87M) | (44.14M) | (83.78M) |
| Depreciation & Amortization | 2.96M | 2.39M | 1.35M | 718K | 548K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.82M | 4.38M | 2.69M | 7.1M | 7.62M |
| Change in Working Capital | (1.73M) | 32.01M | (5.34M) | (9.96M) | 12.18M |
| Accounts Receivables | (5.35M) | 7.35M | (3.07M) | 1.09M | (10.37M) |
| Inventory | (1.58M) | (1.74M) | (989K) | 725K | (126K) |
| Accounts Payables | 1.23M | 1.63M | (1.02M) | 2.78M | 19.52M |
| Other Working Capital | 3.98M | 24.77M | (259K) | (14.56M) | 3.16M |
| Other Non-Cash Items | 29.51M | 5.85M | 2.8M | 10.52M | 11M |
| Operating Cash Flow | (32.98M) | (9.79M) | (6.38M) | (35.76M) | (52.43M) |
| Capital Expenditures | (913K) | (2.52M) | (995K) | (159K) | (562K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (913K) | (2.52M) | (995K) | (159K) | (562K) |
| Debt Repayment | 0 | (2.03M) | (20.39M) | (23K) | (37K) |
| Common Stock Issued | 29.78M | 13.59M | 8.91M | 83.76M | 103.46M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 329K | 1K | 15.45M | (142K) | (810K) |
| Financing Cash Flow | 30.11M | 11.56M | 3.97M | 83.59M | 102.62M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (3.78M) | (751K) | (3.4M) | 47.67M | 49.62M |
| Free Cash Flow | (33.89M) | (12.31M) | (7.38M) | (35.92M) | (52.99M) |
Aquestive Therapeutics, Inc.
NASDAQ:AQST
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.